A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single And Multiple Doses Of CSL040 In Healthy Adult Subjects
Latest Information Update: 08 Dec 2024
At a glance
- Drugs CSL-040 (Primary)
- Indications Reperfusion injury
- Focus Adverse reactions; First in man
- Sponsors CSL Behring
Most Recent Events
- 07 Nov 2024 Planned End Date changed from 1 Mar 2025 to 30 Apr 2025.
- 07 Nov 2024 Planned primary completion date changed from 1 Mar 2025 to 30 Apr 2025.
- 17 Apr 2024 Planned End Date changed from 1 Nov 2024 to 1 Mar 2025.